Drug Search Results
More Filters [+]

Ulotaront

Alternative Names: ulotaront, sep-363856, sep363856, sep 363856
Latest Update: 2024-02-02
Latest Update Note: Clinical Trial Update

Product Description

For schizophrenia and parkinson's disease psychosis (Sourced from: https://www.sumitomo-pharma.com/rd/clinical/pipeline.html)

Mechanisms of Action: TAAR1 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: Sunovion

Clinical Description

Map of Global Clinical Trials for Ulotaront

Countries in Clinic: Bulgaria, China, Colombia, Croatia, Japan, Latvia, Malaysia, Philippines, Romania, Russia, Serbia, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 23

Highest Development Phases

Phase 3: Depressive Disorder, Major|Generalized anxiety disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2071210003

P3

Recruiting

Schizophrenia

2025-09-30

NCT05593029

P3

Recruiting

Depressive Disorder, Major

2025-05-01

95%

DA801201

P3

Recruiting

Schizophrenia

2025-03-31

95%

DA801202

P3

Recruiting

Schizophrenia

2025-03-31

95%

Recent News Events